| Not Yet Recruiting | A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Non-Small Cell Lung Cancer | Phase 2 | 2026-03-31 |
| Not Yet Recruiting | PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC Lung Adenocarcinoma | Phase 2 | 2026-01-31 |
| Recruiting | A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advan Non Small Cell Lung Cancer | Phase 2 | 2025-12-15 |
| Recruiting | Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages | Phase 2 | 2025-11-05 |
| Recruiting | IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation Lung Cancer (Non-Small Cell) | Phase 2 | 2025-11-03 |
| Not Yet Recruiting | A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China Lung Cancer (NSCLC) | — | 2025-10-01 |
| Not Yet Recruiting | QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC NSCLC | Phase 2 | 2025-08-01 |
| Not Yet Recruiting | Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinom Neoadjuvant Non-Small Cell Lung Cancer | Phase 3 | 2025-03-01 |
| Not Yet Recruiting | Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC Non-Small Cell Lung Cancer | N/A | 2024-11-01 |
| Active Not Recruiting | Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis | Phase 4 | 2024-08-01 |
| Recruiting | Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC ALK Positive Non-small Cell Lung Cancer | Phase 2 | 2023-08-18 |
| Recruiting | Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Tre Small-cell Lung Cancer | Phase 2 | 2023-07-10 |
| Recruiting | Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC MRD | Phase 2 | 2022-09-13 |
| Unknown | Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD Non Small Cell Lung Cancer | — | 2022-08-01 |
| Recruiting | MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Mo Lung Cancer | Phase 3 | 2022-06-20 |
| Active Not Recruiting | Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC Carcinoma, Non-Small-Cell Lung | Phase 2 | 2022-05-31 |
| Unknown | Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC Lung Cancer | Phase 2 | 2021-08-01 |
| Unknown | Efficacy and Safety of Camrelizumab in Real-World Prospective Study Non-small Cell Lung Cancer | — | 2021-04-01 |
| Unknown | Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative Non-Small-Cell Lung Cancer | Phase 3 | 2021-03-05 |
| Unknown | Efficacy and Safety of Camrelizumab in Real-World Study Non-small Cell Lung Cancer | — | 2020-11-30 |
| Unknown | Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study NSCLC | — | 2020-10-07 |
| Unknown | An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases | Phase 2 | 2020-08-01 |
| Recruiting | Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy Lung Neoplasms | N/A | 2020-06-01 |
| Unknown | A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Comb Lung Squamous Cell Carcinoma Stage IV | — | 2020-03-01 |
| Unknown | Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer Nsclc | Phase 2 | 2020-03-01 |
| Unknown | A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carbo Non Small Cell Lung Cancer | Phase 2 | 2019-08-08 |
| Unknown | Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients NSCLC | N/A | 2019-07-01 |
| Recruiting | The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China Immunotherapy, Lung Cancer | — | 2019-05-01 |
| Unknown | Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC Advanced Non-squamous NSCLC | Phase 4 | 2018-11-26 |
| Unknown | A Non-interventional Retrospective Study on Overall Survival in Completely Resected Chinese NSCLC Patients Wit Overall Survival | — | 2018-08-31 |
| Unknown | A Real World Study Based on NGS (TRUMPRWS) Non-Small Cell Carcinoma of Lung, TNM Stage 4 | — | 2018-08-01 |
| Unknown | The Impact of Neurocognitive Function in Patients With Multiple Brain Metastases Receiving Whole Brain Radiati Brain Metastases | — | 2018-08-01 |
| Unknown | Phase II Umbrella Study Directed by Next Generation Sequencing Carcinoma, Non-Small-Cell Lung | Phase 2 | 2018-07-09 |
| Unknown | PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC Patients Small Cell Lung Cancer, Polygonal Type | — | 2017-01-01 |
| Terminated | Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer Lung Neoplasm Malignant | Phase 2 | 2016-11-01 |
| Unknown | Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure Non-small Cell Lung Cancer | Phase 2 | 2016-04-01 |
| Completed | Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mut NSCLC | Phase 3 | 2016-04-01 |
| Unknown | Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer Non-Small Cell Lung Cancer | Phase 3 | 2015-10-01 |
| Unknown | Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer Small Cell Lung Cancer | Phase 4 | 2015-02-01 |
| Unknown | Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in Carcinoma, Non-Small-Cell Lung | — | 2014-12-01 |
| Unknown | Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Tre Small Cell Lung Cancer | Phase 2 | 2014-06-01 |
| Completed | Third-line Treatment of Gefitinib in NSCLC Patients Non Small Cell Lung Cancer | Phase 2 | 2014-04-07 |
| Terminated | Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation Non-small-cell Lung Cancer | Phase 2 | 2014-03-01 |
| Completed | A Prospective Epidemiologic Study of ALK-Positive NSCLC in China Non-small-cell Lung Cancer | — | 2013-11-11 |
| Completed | Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients Non Small Cell Lung Cancer | — | 2013-08-01 |
| Completed | Dynamic Circulating Tumor Cell (CTC) Changes During the Chemotherapy in NSCLC Carcinoma, Non-Small-Cell Lung, Cell, Circulating Tumor | — | 2012-11-01 |
| Completed | Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer Brain Metastasis, Non Small Cell Lung Cancer | Phase 3 | 2012-10-14 |
| Unknown | Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer Non-small Cell Lung Cancer | Phase 2 / Phase 3 | 2011-12-05 |
| Unknown | Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation Non-small Cell Lung Cancer | Phase 3 | 2011-09-19 |
| Completed | Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cance Non-small Cell Lung Cancer | Phase 3 | 2011-06-01 |